Pierre Kyme
Known title: Chief Business OfficerCIK: 0002028892
Associated companies
Transaction History
| ARMP | ▼ Sell | Tax Withholding | 1,030 | $11K | 3/14/2026 | View on chart |
| ARMP | ▼ Sell | Tax Withholding | 1,027 | $2K | 3/14/2025 | View on chart |
| ARMP | ▼ Sell | Tax Withholding | 1,030 | $11K | 3/14/2026 | View on chart |
| ARMP | ▼ Sell | Tax Withholding | 1,027 | $2K | 3/14/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Armata Secures $3.7M Pentagon Funding for Phase 3 Trial
Armata Pharmaceuticals received $3.7 million in non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its anti-bacterial program, AP-SA02. The company also announced it will present data at the ISSSI 2026 conference showing how genetic diversity in AP-SA02 may enhance its effectiveness against certain Staphylococcus aureus isolates. While the stock recently declined following the funding news, analysts have maintained a positive outlook with a price target of $15.
Armata Secures $3.7M Pentagon Funding for Phase 3 Trial. Armata Pharmaceuticals received $3.7 million in non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its anti-bacterial program, AP-SA02. The company also announced it will present data at the ISSSI 2026 conference showing how genetic diversity in AP-SA02 may enhance its effectiveness against certain Staphylococcus aureus isolates. While the stock recently declined following the funding news, analysts have maintained a positive outlook with a price target of $15.